Daisy Genomics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Daisy Genomics is an early-stage biotech innovator building a next-generation sequencing platform designed to overcome the limitations of current NGS and nanopore methods. Its core technology leverages Surface-Enhanced Raman Spectroscopy (SERS) within proprietary nanochannels to directly read the chemical 'fingerprint' of individual nucleotides, enabling the detection of epigenetic marks and structural variants on ultra-long DNA strands without sample amplification. The company is pre-revenue and research-focused, having secured grant funding and partnerships to advance its platform for applications in research, diagnostics, and therapeutic development, with an initial focus on cancer.

Oncology

Technology Platform

A nanofluidics-based sequencing platform that uses Surface-Enhanced Raman Spectroscopy (SERS) within proprietary metamaterial/plasmonic nanostructures to directly read the chemical fingerprint of individual nucleotides on ultra-long, native DNA strands without amplification or labeling, enabling simultaneous detection of genetic sequence and epigenetic modifications.

Opportunities

The platform addresses a major gap in genomics by directly detecting epigenetic modifications and structural variants on ultra-long DNA reads, which is critical for advancing precision medicine in oncology and complex diseases.

Partnerships with diagnostic firms like New Day Diagnostics provide a clear path to initial commercial application and validation in high-value clinical areas such as cancer detection.

Risk Factors

The company faces formidable technical risks in scaling its novel nanochip manufacturing and achieving competitive throughput/accuracy.

It must also overcome commercial risks by displacing entrenched sequencing incumbents (Illumina, PacBio, Oxford Nanopore) with massive market share and continuous innovation, all while relying on significant future capital raises in a competitive funding environment.

Competitive Landscape

Daisy Genomics competes in the DNA sequencing market dominated by Illumina (short-read NGS), PacBio (HiFi long-reads), and Oxford Nanopore (electrical signal-based long-reads). Its key differentiator is the direct, amplification-free detection of epigenetics via SERS, a capability not fully offered by current commercial leaders. However, all competitors are actively improving epigenetic detection, making technological execution and speed to market critical.

More companies in Diagnostics & Precision Medicine →More companies in United States →